高血压治疗药物-依普利酮

Eplerenone (Inspra) is a new type of selective aldosterone receptor antagonist. It was approved for clinical use by the State Food and Drug Administration in 2002. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

Clinical trials analyzed the clinical efficacy of eplerenone in the treatment of mild to moderate essential hypertension. Methods 45 patients with mild to moderate hypertension were randomly divided into Losartan group (22 cases) and Eplerenone group (23 cases). The losartan group and the eplerenone group adopted a double-blind, double-simulated, positive drug parallel control method. They were treated with losartan and eplerenone respectively. After 4 weeks of treatment, if the blood pressure did not reach the target, the drug dose was doubled and the treatment was continued for 4 weeks; if the blood pressure reached the target, the original dose was maintained and the treatment was continued for 4 weeks. Results After 8 weeks of treatment, compared with before treatment, the average sitting diastolic blood pressure of the losartan group decreased by (11.33±1.09) mmH g, and the average sitting diastolic blood pressure of the eplerenone group decreased by (13.02±1.40) mmH g. There was no statistical significance between the two groups (P is 0.05). Conclusion Both eplerenone and losartan can effectively reduce the average sitting systolic blood pressure and diastolic blood pressure in patients with hypertension.

The new generation of selective aldosterone antagonist eplerenone (Eplerenone, Inspra) was first launched in the United States in 2002 and applied for patent protection in China in 2006. It is not currently available in the country. For domestic patients, the highly cost-effective Indian eplerenone can be obtained through domestic professional overseas medical service institutions. Eplerenone 50mg✘100 tablets from Lupine Pharmaceuticals in India is about $500. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.